Helen's Pink Sky Foundation Launches to Accelerate Research for Batten Disease and Provide Support to Affected Families
Batten disease is a rare, genetically inherited disorder that affects approximately 2 to 4 children in every 100,000 births. Part of a group of progressive neurodegenerative conditions known as neuronal ceroid lipofuscinoses (NCLs), the disease causes devastating and life-altering symptoms such as developmental regression, seizures, blindness, and dementia. Though rare, its impact on families is unimaginable-and Helen's Pink Sky Foundation is stepping forward to change that.
Helen Born is a three-year old, happy and cheerful toddler. She became the inspiration behind the foundation after her diagnosis with Late Infantile Batten Disease (CLN2), which causes severe and rapidly progressing symptoms including seizures, vision loss, and cognitive decline. While therapies like Enzyme Replacement Therapy (ERT) can slow progression and improve quality of life, there is still no cure.
Through fundraising and donations, Helen's Pink Sky Foundation is committed to supporting world-class scientists and researchers working on gene, cellular, enzyme replacement, and small molecule therapies. By accelerating the development of these breakthrough treatments, the foundation aims not only to improve the quality and length of life for those affected by Batten disease, but ultimately to help find a cure. Equally important is our mission to support families impacted by this devastating and fast-progressing disease by raising awareness, providing essential resources, and building a strong community that drives earlier diagnoses and fuels continued research momentum.
'As Helen's parents, we can't accept Enzyme Replacement Therapy (ERT) being the only FDA approved option for helping children with CLN2. While we're thankful for ERT's ability to possibly slow progression, the end result is not something that we can imagine or accept. We are determined to fight for our sweet Helen, fund research and find a cure for CLN2 and Batten Disease. We will not let a day go by without a fight as that is what Helen deserves!' said Dan and Stephanie Born. 'Time is not on our side, we need to act quickly to move some of this promising research forward now.'
'We're committed to helping families like ours who are battling Batten disease. This is not just about finding a cure, but also about improving the lives of those who are living with this devastating disease. Today, we stand up in unity to take back what Batten rips away from the afflicted families and we start our long fight to bring back smiles, bike rides, giggles, and all the magical things that childhood should be filled with, " said Nick Schneider, Helen's uncle, a founding member of the Helen's Pink Sky Foundation, and President and CEO of Arctic Wolf, a Minnesota-based cybersecurity company.
By supporting critical research and offering practical resources, we hope to change the future for those affected by Batten disease and other neurodegenerative conditions. For more information on the Helen's Pink Sky Foundation, how you can help, or to make a donation, please visit our website at hope4helen.org.
Helen's Pink Sky Foundation is committed to advocacy, research and care for Batten Disease & CLN2. Through our platform, you can stay up to date on Helen's journey, contribute to the cause, and be a part of our growing community dedicated to supporting affected families. Together we will beat this.
For press inquiries:
P: 202-340-0518
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Indianapolis Star
3 days ago
- Indianapolis Star
Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides
SHELTON, CT / ACCESS Newswire NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the 'Company'), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses cannot escape, announced that its drug candidate NV-387 is the weapon necessary for combatting growing cases of measles worldwide, especially in the industrialized world including, USA, Canada, UK, and European Union. NV-387 is possibly the only drug candidate that has been shown to be effective and safe in animal model studies of Measles virus in humanized h-CD150+ knock-in mice, as reported previously by NanoViricides. NV-387 has completed a Phase I clinical trial with no reported adverse events, indicating excellent safety and tolerability in humans. The development of NV-387 as a treatment for Measles can be accelerated under the US FDA programs. Measles is considered a rare orphan disease in the USA. As such, NV-387 for the treatment of Measles would qualify for an Orphan Drug Designation. Orphan drug designation qualifies sponsors for incentives including tax credits for qualified clinical trials, exemption from user fees, and potential seven years of market exclusivity after approval [1]. The Company also plans to explore a 'Fast Track' designation for the NV-387 Measles indication. If granted, a drug approval can occur on the basis of a successful Phase II clinical trial without requiring a Phase III clinical trial, which significantly reduces the timeline to approval. Measles has become an important disease of concern globally in the recent years for several reasons. Most importantly, Measles disease can wipe out the previously learned immunity of the patient against many infections, including from prior infections, and non-live virus vaccines, making the population vulnerable to viruses that were encountered previously. This is because Measles virus attacks the CD150-bearing immune cells that are responsible for memorizing the prior infections and mounting defenses against them later. Measles is possibly the most communicable diseases, spreading through aerosol, that is known to humans. In patients, it produces severe morbidity with skin rash, pain, fatigue, and other syndromes. Rarely it can cause a brain disease. Measles mostly affects children. There were a total of 1,319 confirmed measles cases reported in the USA as of July 22, breaking the most recent record of 1,274 cases in 2019. Hospitalization rates for measles in the USA are about 13%, and fatalities are rare, although in 2025 there were three deaths to date. Canada is having a much worse Measles season than the USA, with more than 3,800 cases [2] to date in 2025. A Measles holiday warning has been issued in the UK this year [3]. England itself had more than 3,000 cases of Measles in 2024. In the European Region, 127,350 measles cases were reported for 2024, double the number of cases reported for 2023 and the highest number since 1997, according to an analysis by WHO and the United Nations Children's Fund (UNICEF) [4]. Worldwide, Measles cases continue to occur every year. Globally, there have been about 108,000 confirmed measles cases in 2025 to date, while in 2024 there were about 360,000 confirmed cases, according to the WHO [5]. A sustained measles vaccination rate of at least 95% is estimated to be required to maintain community immunity ('herd immunity'). Such a high rate is becoming increasingly difficult to achieve even in developed countries where access to vaccination is not an issue. While growing vaccine hesitancy is considered an important reason for the fall in Measles vaccination rates, two other factors are of importance as well: (i) The overall population in the industrialized world, as well as in developing world, has increased frequency of immune dysfunction, obesity, and diabetes. The people with immune dysfunction or immune compromise are less likely to benefit from almost any standard vaccination as compared to healthy people and are likely to result in breakthrough infections. (ii) Additionally, the current vaccine for Measles is a live attenuated vaccine of the 1968 era, and the virus has evolved well past that, although so far the Measles virus strains continue to be susceptible to antibodies produced from the standard vaccine; this can change with continuing circulation of the virus in vaccinated persons and can result in a virus that can substantially defeat the vaccine [6]. Further, vaccine hesitancy itself is not irrational because the standard Measles vaccine is a live attenuated vaccine to be given to infants at early age; it is a virus infection that continues to remain in the subject, which is why it provides lifelong immunity. Measles infection itself also provides lifelong immunity that includes the current strains of the virus. Thus, the Company projects continuing Measles cases worldwide, that require a drug to control the disease in the patient and its spread to others. We believe NV-387 fills this important medical need. There is no approved drug for treatment of Measles at present. ABOUT NANOVIRICIDES NanoViricides, Inc. (the 'Company') ( is a publicly traded (NYSE-American, stock symbol NNVC) clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments. The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials. The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product. This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading 'Risk Factors' and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products. The phrases 'safety', 'effectiveness' and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA. FDA refers to US Food and Drug Administration. IND application refers to 'Investigational New Drug' application. cGMP refers to current Good Manufacturing Practices. CMC refers to 'Chemistry, Manufacture, and Controls'. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for 'Active Pharmaceutical Ingredient'. WHO is the World Health Organization. R&D refers to Research and Development. Public Relations Contact: ir@ View the original press release on ACCESS Newswire The post Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides appeared first on DA80 Hub.
Miami Herald
4 days ago
- Miami Herald
Atlas Salt Supports Memorial University Researchers with their Passive Array for Critical Minerals on the Island of Newfoundland
ST. GEORGE'S, NEWFOUNDLAND AND LABRADOR / ACCESS Newswire / August 7, 2025 / Atlas Salt Inc. ("Atlas Salt" or the "Company") (TSXV:SALT)(OTCQB:REMRF) announces that it is actively supporting Memorial University of Newfoundland ("Memorial University") researchers with their Passive Array for Critical Minerals on the Island of Newfoundland ("PACMIN") to help to better understand the geological structures and the plate-tectonic processes that assembled the island hundreds of millions of years ago. PACMIN is a joint initiative between Memorial University, Université du Québec à Montréal, and Yale University, with financial and in-kind support from Natural Resources Canada and select business partners. It has deployed a new network of 22 seismograph stations across Newfoundland to record ground vibrations and use these signals to image the internal structure of the Earth beneath Newfoundland. This information will improve the understanding of the deep tectonic processes that played a role in the island's formation and will help to better determine the location of critical minerals that are needed to facilitate the transition to a greener economy, a goal consistent with Atlas Salt's business objectives. In support of this initiative, PACMIN has installed a seismograph at one of Atlas Salt's facilities in St. George's. The PACMIN project will run through the end of summer 2027. Dr. J. Kim Welford, Principal Investigator for PACMIN and Associate Professor, Department of Earth Sciences, Memorial University, commented, "Enhanced knowledge of the geological structure of Newfoundland could help to provide economic benefits for future generations of Newfoundlanders. We are pleased that corporate citizens of the Island of Newfoundland, particularly those with a direct involvement in the mining community such as Atlas Salt, have offered their assistance with the PACMIN project." Nolan Peterson, CEO of Atlas Salt, added, "We are excited to be supporting Memorial University researchers on this initiative. Atlas Salt has a strong commitment to increasing mining activities and initiatives in the Province of Newfoundland and Labrador, and we believe the knowledge gained through the PACMIN project will be of tremendous benefit in this respect. We look forward to building our relationship with Memorial University, and we anticipate additional collaborations with academia in the future." About Atlas Salt Atlas Salt is developing Canada's next salt mine and is committed to responsible and sustainable mining practices. With a focus on innovation and efficiency, the company is poised to make significant contributions to the North American salt market while upholding its values of environmental stewardship and community engagement. For information, please contact: Jeff Kilborn, CFO & VP Corporate Developmentinvestors@ 275-2009 We seek safe harbor. Cautionary Statement Neither the TSX Venture Exchange nor its Regulation Services Provider, (as the term is defined in the Policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This press release includes certain "forward-looking information" and "forward-looking statements" (collectively "forward-looking statements") within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein, without limitation, statements relating to the future operating or financial performance of the Company, are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "estimates", "potential", "possible", and similar expressions, or statements that events, conditions, or results "will", "may", "could", or "should" occur or be achieved. Forward-looking statements in this press release relate to, among other things: obtaining financing, completion, delivery and timing of project components and requirements, and analysis and assumptions related thereto. Actual future results may differ materially. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made and are based upon a number of assumptions and estimates that, while considered reasonable by the respective parties, are inherently subject to significant business, technical, economic, and competitive uncertainties and contingencies. Many factors, both known and unknown, could cause actual results, performance or achievements to be materially different from the results, performance or achievements that are or may be expressed or implied by such forward-looking statements and the parties have made assumptions and estimates based on or related to many of these factors. Such factors include, without limitation: the timing, completion and delivery of required permits, supply arrangements and financing. Readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times. Except as required by law, the Company does not assume any obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. SOURCE: Atlas Salt Inc.
NBC News
5 days ago
- NBC News
Director Francis Ford Coppola doing 'fine' after cardiac procedure in Rome
LOS ANGELES — Francis Ford Coppola, the acclaimed American director of 'The Godfather' movies and 'Apocalypse Now,' underwent a non-emergency cardiac procedure in a Rome hospital and is doing fine, he and a U.S.-based representative said on Tuesday. 'Mr. Coppola went in for a scheduled update procedure' performed by renowned Italian-born cardiologist Dr. Andrea Natale 'and is resting nicely,' the representative said in response to Italian media reports that the director was hospitalized. 'All is well.' Coppola, 86, has been a patient of Natale for more than 30 years, the representative said. The filmmaker was admitted on Tuesday to the Policlinico Tor Vergata, a public hospital in the Italian capital, news agency ANSA reported. The U.S.-based representative declined to give any details about the nature of Coppola's medical procedure, but said: 'There was not an emergency. He went to the hospital in a car. He had a scheduled appointment.' Coppola posted a photograph of himself on Instagram appearing relaxed and smiling with a message reassuring fans, 'I am well.' 'Da Dada (what my kids call me) is fine, taking an opportunity while in Rome to do the update of my 30-year-old afib procedure with its inventor, a great Italian doctor — Dr. Andrea Natale,' it said. He did not elaborate further. The term 'a-fib' in medical parlance is short for atrial fibrillation, a type of abnormal heart rhythm. Natale, currently the executive director of the Texas Cardiac Arrhythmia Institute, is an electrophysiology specialist who pioneered several treatments and devices for the treatment of such disorders. Coppola was in Italy to promote his latest movie, the science-fiction epic 'Megalopolis,' a $120 million self-funded production about a visionary architect's quest to transform a futuristic version of New York City called New Rome into a utopian community. The film, which has drawn mixed reviews and struggled at the box office following its 2024 debut at the Cannes Film Festival, was reported to have received a special screening at the Magna Graecia Film Festival in Catanzaro, Italy. The Italian-American director has won five Academy Awards, four of them for his work on the first two films in 'The Godfather' trilogy, widely considered by cinema buffs to rank among the greatest movies of all time.
